Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide multiple-dose PK/PD study in healthy volunteers
NL-OMON48146Active, not recruiting
- Sponsor
- VectivBio
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of apraglutide in short bowel syndrome (SBS) (4 arms), sponsored by VectivBio. Primary endpoints: Treatment-emergent adverse events, Concomitant medication and 15 more. Started May 2019; status: active, not recruiting.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON48146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48146.